DKTK-Studienregister

DetailsucheDetailsuche
Klicken Sie auf Detailsuche, um z.B. nach Therapielinie, molekularem Marker oder Rekrutierungsstatus zu suchen.
FreitextsucheFreitextsuche
Sie können hier nach dem Studienkurzcode oder einem Teil des Studientitels suchen.
Studienauswahl
Zentren
Status der Studie

» Gynäkologische Onkologie » Mamma-Ca

Alle Linien

AMGEN T-VEC_Atezolizumab
The goal of this study is to evaluate the safety of intrahepatic injection (directly into the liver) of talimogene laherparepvec in combination with intravenously administered atezolizumab in subjects with triple negative breast cancer and colorectal cancer with liver metastases. (Aktiv)

LIBRE
Prospektive randomisierte multizentrische Studie zur Untersuchung der Machbarkeit eines strukturierten körperlichen Bewegungsprogramms und einer mediterranen Ernährung bei Frauen mit BRCA1/2-Mutationen (Aktiv)

LIBRE-2
Efficacy of Lifestyle Intervention in BRCA1/2 Mutation Carriers (Aktiv)

Oligoma
randomisierte, multizentrische Prüfung der Wirksamkeit und Sicherheit einer lokalen Strahlentherapie von Metastasen als Ergänzung zur Standardtherapie bei Patientinnen mit oligometastasiertem Mamma-Carcinom (Aktiv)

OlympiaN (D931CC00001)
A Phase II, Multicentre, Open-Label Study to Assess the Efficacy and Safety of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination as Neoadjuvant Therapy in Patients With BRCA Mutations and Early Stage HER2-Negative Breast Cancer (Aktiv)

OnkoFit I
Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Adjuvant Radiotherapy of Breast Cancer (Aktiv)

RIBBIT
Klinische Studie zur Untersuchung der Wirksamkeit und der Lebensqualität von postmenopausalen Patientinnen mit metastasiertem HER2-negativem, Hormonrezeptor-positivem Brustkrebs unter Erstlinienbehandlung mit einer Kombinationstherapie aus Ribociclib und einem Aromataseinhibitor oder einer Therapie mit Paclitaxel mit / ohne Bevacizumab (Aktiv)

SAVE-HEART
Cardiac Safety Study in Patients With HER2 + Breast Cancer (SAFE-HEaRt) (Aktiv)

Seno_Ex_MAC 003
Comparison of Conventional With Sonography Assisted Breast Surgery (Aktiv)

Seno_Ex_MARGIN-II
MOLEKULARE FLUORESZENZ-GESTEUERTE OPERATION UNTER ANWENDUNG VON BEVA800 ZUR BEWERTUNG VON TUMORRÜCKSTÄNDEN (Aktiv)

TNBC-MORPHEUS
A Study to Evaluate Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Metastatic Triple-Negative Breast Cancer (MORPHEUS-TNBC) (Aktiv)

UC02-PSMA-01
Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker (Aktiv)

VIOLETTE
A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair (Aktiv)

Erstlinie

ADAPT
Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer (Aktiv)

ADAPT Elderly
A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response (Aktiv)

ATZ-1068-KRA-20I
HER2-Peptide Vaccination of Patients With Solid Tumors (Aktiv)

AXSANA
Prospektive, multizentrische Registerstudie zur Bewertung verschiedener leitlinienkonformer Operationsverfahren in der Axilla (Sentinel-Node Biopsie, Targeted Axillary Dissection, Axilladissektion) nach neoadjuvanter Chemotherapie (Aktiv)

BENEFIT
Exercise Interventions for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy (Aktiv)

BZ_neoMono (neoMono)
Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (Aktiv)

CAPTOR-BC
Comprehensive analysis of spatial, temporal and molecular patterns of Ribocicib and resistance in advanced breast cancer patients (Aktiv)

CARL
Feasibility of extracorporeal elimination by double membrane plasmapheresis (Aktiv)

COGNITON-GUIDE
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer - a Multicenter, Open-label, Umbrella Phase-II Study - COGNITION-GUIDE (Aktiv)

COSMOPOLITAN
Intraoperative Electron Radiotherapy for Low-risk Early Breast Cancer (Aktiv)

ECLIPSE
A phase II study investigating preoperative combination strategies for immunotherapy in patients with untreated, operable oestrogen receptor positive primary breast cancer (Aktiv)

Ember 2
A Phase 1, Open-Label, Preoperative Window Study evaluating the Biological Effects of LY3484356 in Post-menopausal Women with Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer (Aktiv)

Expression
Neoadjuvant, sequential chemotherapy with docetaxel followed by Fluorouracil, Epirubicin, and Cyclophosphamid every 3 weeks - genome wide expression analysis for identification of a predictive gene signature in patients with primary breast cancer (Aktiv)

GALADON
Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON) (Aktiv)

INSEMA (GBG 75)
The objective of INSEMA is to show that less axillary surgery is better, in that oncological outcomes are the same and less surgical intervention will result in fewer surgical complications. (Aktiv)

IPATunity 130
This study will evaluate the efficacy of ipatasertib + paclitaxel versus placebo + paclitaxel in participants with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC) and in participants with locally advanced or metastatic hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2−) breast adenocarcinoma who are not suitable for endocrine therapy. (Aktiv)

Impassion 131
A PHASE III, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER (Aktiv)

PALLAS
A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive/HER2-negative early breast cancer (Aktiv)

PIKTAM
Clinical trial of BKM120 in combination with tamoxifen in patients with breast cancer (hormone receptor-positive, HER2-negative, inoperable, locally advanced or metastatic) (Aktiv)

PREPARE
Prevention of paclitaxel-related neurological side effects with lithium carbonate – a randomized, double-blind, placebo-controlled, explorative proof-of-concept phase II clinical trial to counteract chemotherapy induced neurotoxicity (PREPARE trial) (Aktiv)

SGNLVA-002
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer (Aktiv)

Zweitlinie oder später

ADAPTlate
Adjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy in (Clinical or Genomic) High Risk, HR+/HER2- Early Breast Cancer (ADAPTlate) (Aktiv)

CNIR178X2201
Study of efficacy and safety of NIR178 and PDR001 combination in patients with selected solid tumors and non-Hodgkin lymphoma (Aktiv)

CO44194
A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (Aktiv)

DESTINY-Breast06 (D9670C00001)
Eine randomisierte, multizentrische, offene Phase-III-Studie mit Trastuzumab Deruxtecan (T-DXd) im Vergleich zur Chemotherapie nach Wahl des Prüfarztes bei HER2-niedrigen, hormonrezeptorpositiven Brustkrebspatientinnen, deren Erkrankung während einer endokrinen Therapie im metastasierten Setting fortgeschritten ist (Aktiv)

DESTINY-Breast12 (D9673C00007)
Eine offene, multinationale, multizentrische Phase-IIIb/IV-Studie mit Trastuzumab Deruxtecan bei Patienten mit oder ohne zu Studienbeginn vorliegender Hirnmetastasierung mit vorbehandeltem fortgeschrittenem/metastasiertem HER2-positivem Brustkrebs (Aktiv)

DS8201-A-U105 - Daiichi Sankyo
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer (Aktiv)

Detect IV
An open label, non-randomized phase II trial of Everolimus (Aktiv)

ELECTRA
An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer (Aktiv)

EPIK-B5
EPIK-B5: A Phase III, Randomized, Double-blind, Placebo-controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With HR-positive, HER2-negative Advanced Breast Cancer With a PIK3CA Mutation, Who Progressed on or After Aromatase Inhibitor and a CDK4/6 Inhibitor (Aktiv)

Imcheck ICT01-101 (EVICTION)
First-in-Human Study of ICT01 in Patients With Advanced Cancer (Aktiv)

MK-7684A-005
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (Aktiv)

MedOPP068
PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (Aktiv)

NATALEE
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer (Aktiv)

Novartis CFKA115A12101
A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Tislelizumab in Patients With Select Advanced Cancers (Aktiv)

PADMA
The study aims to compare the time-to-treatment failure of a palbociclib + endocrine therapy against a pre-chosen mono-chemotherapy in a real world setting. Time-to-treatment failure (TTF) is defined as time from randomization to discontinuation of treatment due to disease progression, treatment toxicity, patient’s preference, or death. (Aktiv)

SASCIA
Phase III Studie zur postneoadjuvanten Behandlung mit dem Antikörper Medikamenten Konjugat Sacituzumab Govitecan bei Frauen mit frühem, HER2- negativem Brustkrebs und hohem Rückfallrisiko nach einer Standardbehandlung im neoadjuvanten Setting (Aktiv)

SORATRAM
Multizentrische Basket-Studie zur kombinierten CRAF- und MEK-Inhibition bei fortgeschrittenen Tumorerkrankungen mit BRAF-Mutationen und eingeschränkter Kinase-Aktivität (Aktiv)

VALO-001
Phase I Studie zu einer Erstlinientherapie bei Nicht-Kleinzelligem Lungenkarzinom, Schwarzem Hautkrebs oder Brustkrebs (Aktiv)

Viktoria-1
A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (Aktiv)

eVera
A randomized, open-label, multicenter phase III study to evaluate the efficacy and safety of giredestrant plus everolimus compared to exemestane plus everolimus in patients with estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. (Aktiv)

DKTK-Studienregister
Dr. N. Gökbuget, Dipl.-Biol. K. Ihrig | Ohne Gewähr für Richtigkeit oder Vollständigkeit | ccp@dkfz.de